title: Altered parietal-motor connections in Alzheimer's disease patients.
abstract: Alzheimer's disease (AD) is characterized by altered functional cortico-cortical connectivity likely due to loss of afferent and efferent connections between different cortical areas. Here we explored parieto-frontal functional connectivity in 15 AD patients and 12 healthy control subjects by means of bifocal transcranial magnetic stimulation (TMS). Conditioning stimuli were applied over the right posterior parietal cortex (PPC) at different intensities (90% and 110% of resting motor threshold, RMT). Motor evoked potentials (MEPs) were then recorded from the ipsilateral primary motor cortex at different interstimulus intervals (ISIs) ranging between 2 and 15 ms. Results showed that in healthy subjects, a conditioning TMS pulse applied over the ipsilateral PPC at 90%, but not at 110%, of RMT intensity was able to increase the excitability of the right M1. This functional interaction peaked at ISI = 6 ms. Conversely, in AD patients the facilitatory pattern of parieto-motor connections was evident only when TMS was delivered at an intensity of 110% of RMT with a peak at ISI = 8 ms. Moreover in AD patients, treatment with cholinesterase inhibitors did not induce any significant modification in the strength of the connection. In subsequent analyses, we found that, in AD patients, the effects induced by PPC conditioning at 110% RMT correlated with neuropsychological measures of episodic memory and executive functions, implying that patients with better cognitive performance had less impaired connectivity. Our findings reveal that parieto-frontal cortico-cortical functional connectivity is altered in AD patients, providing further evidence for a disconnection-based interpretation of AD symptoms.
authors.affiliation: IRCCS Fondazione Santa Lucia, Rome, Italy.
authors.forename: Sonia
authors.initials: S
authors.lastname: Bonnì
authors.forename: Federica
authors.initials: F
authors.lastname: Lupo
authors.forename: Emanuele
authors.initials: E
authors.lastname: Lo Gerfo
authors.forename: Alessandro
authors.initials: A
authors.lastname: Martorana
authors.forename: Roberta
authors.initials: R
authors.lastname: Perri
authors.forename: Carlo
authors.initials: C
authors.lastname: Caltagirone
authors.forename: Giacomo
authors.initials: G
authors.lastname: Koch
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004525:Efferent Pathways / Q000473:pathology* / Q000503:physiopathology; D019054:Evoked Potentials, Motor / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D009044:Motor Cortex / Q000473:pathology* / Q000503:physiopathology; D009483:Neuropsychological Tests; D010296:Parietal Lobe / Q000473:pathology* / Q000503:physiopathology; D048448:Phenylcarbamates / Q000627:therapeutic use; D000068836:Rivastigmine; D050781:Transcranial Magnetic Stimulation
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine